Posted by Michael Wonder on 13 Jul 2023
ICER publishes evidence report on gene therapies for sickle cell disease
13 July 2023 - In the short term, both lovo-cel and exa-cel can dramatically reduce the frequency of painful crises in patients with severe sickle cell disease.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of exagamglogene autotemcel (“exa-cel”, Vertex Pharmaceuticals and CRISPR Therapeutics) and lovotibeglogene autotemcel (“lovo-cel”, bluebird bio) for sickle cell disease.
